Liquidia (LQDA) said Monday that United Therapeutics (UTHR) has filed a complaint Friday accusing the company of infringing United's patent.
The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Liquidia Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.
The company said United Therapeutics is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.
United Therapeutics did not immediately respond to a request for comment from MT Newswires.
Price: 15.46, Change: +0.20, Percent Change: +1.31
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。